FDA READI-Home Innovation Challenge: How Medical Device Companies Can Participate in the Race to Reduce Hospital Readmissions

A practical guide to the FDA's READI-Home Innovation Challenge launched April 7, 2026, including eligibility requirements, the two-phase selection process, how to submit an informational Q-submission, and what selected participants gain from early FDA engagement.

Why the READI-Home Challenge Exists

Hospital readmissions are one of the most persistent and costly problems in the U.S. healthcare system. Every year, millions of patients who are discharged from acute care return to the hospital within 30 days — often for reasons entirely unrelated to their original admission. The consequences are personal, financial, and systemic.

The data paints a stark picture:

30-day readmission rates for patients with chronic conditions range from 2.8% to 18.4%, depending on the condition and population.
More than half of these readmissions occur for reasons different from the original hospitalization, suggesting that many are potentially avoidable with better post-discharge support.
Among patients without chronic conditions, the 30-day readmission rate was 13.9% between 2016 and 2020.
Readmissions cost approximately 12% more than the initial hospital stay, creating a compounding financial burden on patients, payers, and the healthcare system at large.

These figures are not merely statistical abstractions. Each readmission represents a patient who left the hospital thinking their acute episode was behind them, only to find themselves back in an inpatient bed within weeks. Each readmission carries risks: hospital-acquired infections, medication errors, disruption to recovery, and the psychological toll of relapse. For elderly patients and those managing multiple chronic conditions, a readmission can mark the beginning of a steep decline.

The Shift Toward Home-Based Care

A parallel trend is reshaping how clinicians, patients, and regulators think about care delivery: the migration of healthcare from the hospital to the home. A 2024 study published in the Journal of the American Medical Association (JAMA) found that 47.2% of surveyed U.S. adults said hospital-at-home care would be acceptable, with similar preferences across age groups. This is not a niche interest confined to digital health enthusiasts — it reflects a genuine shift in patient expectations.

The COVID-19 pandemic accelerated this movement out of necessity. Hospital capacity constraints forced health systems to explore home-based models for monitoring, treatment, and recovery. Many of those experiments proved that care could be delivered safely and effectively outside institutional walls, provided the right tools were in place. The challenge now is building those tools — and ensuring they meet regulatory standards.

FDA's "Home as a Health Care Hub" Initiative

Against this backdrop, FDA's Center for Devices and Radiological Health (CDRH) launched the Home as a Health Care Hub initiative in April 2024, a broad effort to reimagine the home as an integral component of the healthcare system rather than a peripheral one. The initiative recognizes that medical devices used in the home are often designed to operate in isolation, rather than as part of an integrated, holistic environment. Patients may have to use several different medical devices, some of which were not initially designed with the home environment in mind.

As part of this initiative, CDRH developed the Idea Lab — a set of free tools for developers to identify challenges, constraints, and opportunities for people managing medical conditions in their daily lives. The Idea Lab includes the Lilypad virtual reality prototype, which allows users to visualize and build integrative solutions, including new home-use devices, and imagine ways to adapt existing devices to better serve patients in a home environment.

The READI-Home Innovation Challenge is the most concrete and actionable element of this initiative to date. It moves from conceptual exploration to a structured program that offers device developers a direct pipeline to FDA engagement.

What the Challenge Offers

The Reducing Readmissions through Device Innovation for the Home (READI-Home) Innovation Challenge, announced on April 7, 2026, is designed to accelerate patient access to medical device technologies that reduce hospital readmissions. It does this by creating a structured pathway for early and intensive FDA collaboration with a select group of innovators.

At its core, the Challenge offers three things:

1. Early and Iterative FDA Engagement

Selected participants enter an "interaction phase" that includes "sprint" discussions — frequent, structured interactions with FDA review staff that go well beyond the standard pre-submission process. This means rapid-cycle feedback on device design, testing strategies, clinical evidence plans, and regulatory pathways. For companies developing novel home-use devices, this kind of early dialogue can save months or even years of development time by identifying potential issues before resources are committed to a particular approach.

2. Consideration for Breakthrough Device or STeP Designation

Devices described in informational Q-submissions during the selection phase may also be considered for Breakthrough Device (BTD) designation or Safer Technologies Program (STeP) designation, as appropriate. This is a significant opportunity. The Breakthrough Devices Program provides priority review, sprint discussions, senior management involvement, and organizational commitment from FDA — benefits that can materially accelerate the path to market. STeP offers similar benefits for devices that improve the safety of treatments or diagnostics for less severe conditions.

Importantly, BTD and STeP consideration is not automatic — the device must independently meet the relevant designation criteria. But the Challenge creates a natural on-ramp for this consideration.

3. Opportunity to Demonstrate at FDA Research Facilities

Participants in the interaction phase will have the opportunity to demonstrate their technology at FDA's research facilities. This is not a symbolic gesture. Live demonstrations allow FDA staff to see how a device performs, how users interact with it, and how it might behave in a home environment — insights that can materially influence regulatory strategy and evidence requirements.

What the Challenge Is NOT

It is critical to understand what participation does not provide:

Participation does not constitute premarket approval. Selected devices must still complete the appropriate regulatory pathway (510(k), De Novo, or PMA) and meet all statutory requirements for clearance or approval.
The Challenge does not lower the evidentiary standard. FDA's expectations for safety and effectiveness remain unchanged. What changes is the process — earlier engagement, faster feedback, and a collaborative approach to evidence generation.
Participation is not confidential. If your device is selected for the interaction phase, FDA will publicly disclose your company name, the device name, and a description of the device on its public-facing webpage.

Eligibility and Selection Criteria

Device Definition Requirement

To be considered for the READI-Home Innovation Challenge, the proposed innovation must meet the definition of a "device" under Section 201(h)(1) of the Federal Food, Drug, and Cosmetic Act (FD&C Act). This includes:

An instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article, including any component, part, or accessory, which is (A) recognized in the official National Formulary, or the United States Pharmacopeia, or any supplement to them, (B) intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, in man or other animals, or (C) intended to affect the structure or any function of the body of man or other animals, and which does not achieve its primary intended purposes through chemical action within or on the body of man or other animals and which is not dependent upon being metabolized for the achievement of its primary intended purposes.

The term "device" does not include software functions excluded from the device definition pursuant to Section 520(o) of the FD&C Act. Sponsors should carefully assess whether their technology falls within the device definition before investing in a submission.

Five Prioritization Elements

FDA will evaluate submissions against five prioritization elements. A strong submission should clearly address each one:

#	Element	What FDA Is Looking For
1	Unmet healthcare need in the home	The device addresses an unmet or emerging healthcare need where expanded availability in the home setting would be in the best interest of patients.
2	Patient and/or caregiver as intended user	At least one intended user is a patient and/or caregiver, as opposed to the device only being used by a trained medical professional.
3	Home or community use environment	At least one of the intended use environments is in a patient's home and/or community environment. For the purposes of the Challenge, the home environment includes but is not limited to an individual's residence without the continuous presence of trained medical professionals.
4	Evidence of readmission reduction potential	Sufficient evidence (e.g., literature, data) exists to support that the device may be associated with reduction in or prevention of readmission(s) for the target population(s).
5	Demonstrated feasibility	The device has demonstrated feasibility (i.e., the device works as intended based on a proof of concept, prototype, and/or preliminary testing).

These five elements are not binary pass/fail criteria. FDA will use them to prioritize and compare submissions, selecting up to nine devices that best demonstrate alignment with the Challenge's goals. A device that partially meets all five elements may be favored over one that strongly meets three but weakly addresses the remaining two.

Additional Submission Requirements

Beyond the five prioritization elements, FDA will also consider the following information:

Letter	Requirement	Practical Guidance
(a)	Description of the device and the clinical challenge it is intended to address	Clearly describe what the device does, how it works, and the specific clinical problem driving its development. Link the clinical challenge to the readmission problem.
(b)	Novelty of the device/concept	Explain what is new about your approach. Is it a novel technology, a novel application of an existing technology, or a novel combination of technologies? What differentiates it from currently available solutions?
(c)	Current development status of the device	Be transparent about where you are in development. FDA wants to understand maturity level — is this a concept, a bench prototype, a clinical-grade prototype, or a device with preliminary clinical data?
(d)	Data Development Plan (DDP) for the device	Outline your plan for generating the evidence needed to support a future marketing application. This should include bench testing, animal studies (if applicable), human factors studies, and clinical studies.
(e)	Overview of key expertise within the team	Describe the relevant expertise of your team, including regulatory affairs, clinical, engineering, and human factors capabilities. FDA wants confidence that you can execute on the development plan.
(f)	Anticipated impact	Quantify the potential impact of your device on readmission rates, patient outcomes, and healthcare costs where possible. Use literature and preliminary data to support your projections.

One Device per Manufacturer

While a manufacturer may submit information regarding multiple devices, no more than one device per manufacturer may advance to the interaction phase. If your company has multiple candidate devices, you should carefully evaluate which one best aligns with the five prioritization elements and submit the strongest candidate.

The Two-Phase Process

The READI-Home Innovation Challenge is structured as a two-phase program with clearly defined timelines.

Phase 1: Selection Phase

The selection phase encompasses both the submission period and FDA's evaluation of submissions.

Milestone	Date
Challenge announced	April 7, 2026
Submission period opens	April 7, 2026
FDA webinar on the Challenge	June 24, 2026 (1:00 - 2:00 PM ET)
Submission period closes	September 30, 2026
FDA selection period	October 1 - December 4, 2026
Participants notified	By December 4, 2026

The FDA has scheduled a webinar on June 24, 2026 from 1:00 to 2:00 PM ET to discuss the Challenge and answer questions from prospective participants. The webinar will be hosted on Microsoft Webinar and registration is required. Presentation slides and a transcript will be available afterward on the FDA website and at CDRH Learn under "Specialty Technical Topics," sub-section "Home Use."

Phase 2: Interaction Phase

The interaction phase begins on December 5, 2026 for the up to nine selected participants. This phase includes:

Component	Description
Sprint discussions	Frequent, structured interactions with FDA review staff to refine device design, testing strategies, and regulatory approach
Iterative feedback	Rapid-cycle feedback on specific technical and regulatory questions, going beyond what is typically available through standard pre-submissions
Technology demonstrations	Opportunity to demonstrate the device at FDA research facilities, allowing FDA staff to observe device performance and user interaction firsthand
BTD/STeP evaluation	Continued consideration for Breakthrough Device Designation or Safer Technologies Program designation as the device matures
Public recognition	FDA will announce the names of companies and devices selected for the interaction phase on its public-facing webpage

Complete Timeline Overview

Phase	Period	Key Activities
Selection — Submission	April 7 - September 30, 2026	Companies prepare and submit informational Q-submissions through CDRH portal
Selection — FDA Review	October 1 - December 4, 2026	FDA evaluates submissions against prioritization elements and selects up to 9 participants
Notification	By December 4, 2026	FDA notifies all submitters of selection outcomes
Interaction Phase	Beginning December 5, 2026	Selected participants engage in sprint discussions, iterative feedback, and potential technology demonstrations at FDA facilities

How to Prepare Your Submission

The submission requirements are specific and non-negotiable. Failing to follow the formatting and content guidelines will not result in a technical rejection, but it will make a poor impression on reviewers who are evaluating up to nine slots among what may be dozens of applicants.

Submission Format

Requirement	Specification
Executive summary	Limited to 1 page, summarizing how your device meets elements 1-5
Supporting documentation	Maximum 16 total pages (including the executive summary), excluding references
Font	Times New Roman, no smaller than 11-point
Language	English
File format	PDF
Confidential information	Clearly identify any trade secret or confidential commercial information

What to Include in the Executive Summary

The one-page executive summary is arguably the most important part of your submission. It should concisely address how your device meets each of the five prioritization elements. Think of it as a structured pitch:

What unmet need does your device address in the home setting? Be specific about the clinical gap and the patient population.
Who will use it? Confirm that patients and/or caregivers are intended users, not just healthcare professionals.
Where will it be used? Explicitly state the home and/or community use environment.
How might it reduce readmissions? Reference literature, preliminary data, or analogous evidence that supports the readmission reduction potential.
Does it work? Summarize feasibility evidence — proof of concept, prototype testing, or preliminary results.

What to Include in the Supporting Documentation

The supporting documentation (up to 15 pages after the executive summary) should address items (a) through (f):

Device description and clinical challenge (a): Provide a detailed technical description of the device, its mechanism of action, and the specific clinical challenge it addresses. Connect this directly to the readmission problem — what happens today without your device, and how does your device change that trajectory?
Novelty (b): Differentiate your approach from existing solutions. If there are predicate devices or comparable technologies, explain why yours is different and why that difference matters for home-based readmission reduction.
Development status (c): Provide a honest assessment of where you are. Include details on prototype development, bench testing, animal studies, and any preliminary clinical data. FDA values transparency over optimism.
Data Development Plan (d): This is critical. Outline your evidence generation strategy, including planned bench testing, human factors studies, clinical study design (if applicable), and how each element supports a future marketing application. A well-constructed DDP signals that you understand the regulatory landscape and have a credible path forward.
Team expertise (e): Describe the qualifications and relevant experience of your core team members, with emphasis on regulatory affairs, clinical development, engineering, and human factors. If you have advisors or consultants with FDA interaction experience, mention them.
Anticipated impact (f): Quantify the potential impact where possible. How many patients could benefit? What readmission reduction could be achieved? What are the cost savings implications? Support projections with literature or data.

How to Submit

Submissions are made through the CDRH portal as an Informational Q-submission. Two specific formatting requirements must be followed:

Company Name field: Prefix with "READI-Home Innovation Challenge"

Example: READI-Home Innovation Challenge – DeviceCompanyName
Submission Purpose field: Include the following exact text:

This informational Q-submission provides information related to a medical device innovation intended to reduce or eliminate hospital readmission following post-acute hospital stays, consistent with the goal of the READI-Home Innovation Challenge. I understand this Q-submission will be reviewed by relevant CDRH staff for potential Breakthrough Devices (BTD) designation or Safer Technologies Program (STeP) designation as described for the Innovation Challenge, and may or may not result in a face-to-face meeting with the FDA. Regardless of the outcome of this review, I understand that I may still submit subsequent Q-submissions related to this medical device innovation. If my device is selected for the interaction phase of the READI-Home Innovation Challenge, I understand and agree that FDA will publicly disclose this participation in the Innovation Challenge, including the name and a description of my device and the name of the submitting company/organization, and I am duly authorized to agree to such disclosure.

Note the acknowledgment within the submission purpose statement: by submitting, you agree that if selected, FDA will publicly disclose your participation, including the name and description of your device and your company name. Ensure that the person submitting is duly authorized to make this commitment on behalf of the organization.

Questions and Contact

If you have questions about the Challenge, contact FDA at HealthHomeHub@fda.hhs.gov with the subject line "READI-Home Innovation Challenge Inquiry."

What Selected Participants Get

For the up to nine companies selected for the interaction phase, the program offers tangible regulatory and strategic advantages.

Sprint Discussions

The centerpiece of the interaction phase is the sprint discussion model. Unlike traditional pre-submission meetings, which are typically one-time events with defined agendas and formal feedback letters, sprint discussions are ongoing, iterative conversations with FDA experts. They allow for:

Rapid-cycle feedback: Submit questions, design proposals, or test results and receive FDA input quickly, without waiting for the formal pre-submission timeline.
Course correction: Identify potential issues early and adjust your development strategy before committing resources to a flawed approach.
Relationship building: Develop a working relationship with the FDA review team that will be involved in any future marketing application, creating a foundation of mutual understanding.

FDA Research Facility Demonstrations

The opportunity to demonstrate your technology at FDA research facilities is a unique benefit of the Challenge. This is not the same as submitting test data in a 510(k) or PMA. It is a live, interactive demonstration that allows FDA scientists and engineers to observe:

How the device performs in real-time
How users (patients, caregivers) interact with the device
How the device might behave in a simulated home environment
Potential failure modes or usability issues that might not be apparent from documentation alone

These demonstrations can generate insights that shape FDA's understanding of the technology and inform the evidence requirements for a future marketing application.

Breakthrough Device and STeP Designation Consideration

As noted earlier, devices submitted to the Challenge may be considered for Breakthrough Device Designation or Safer Technologies Program designation. Each program offers distinct advantages:

Program	Focus	Key Benefits
Breakthrough Device Designation (BTD)	Devices for life-threatening or irreversibly debilitating conditions	Priority review, sprint discussions, senior management involvement, organizational commitment, efficient device development
Safer Technologies Program (STeP)	Devices that improve the safety of treatments or diagnostics for non-life-threatening conditions	Similar interactive benefits to BTD, including sprint discussions and priority review, for devices targeting conditions that are not life-threatening or irreversibly debilitating

The key distinction is the severity of the target condition. BTD requires a life-threatening or irreversibly debilitating condition; STeP covers a broader range of conditions where improved safety is the primary benefit. For many home-use devices aimed at reducing readmissions, STeP may be the more appropriate program, particularly if the target condition is chronic but not immediately life-threatening.

Public Recognition

FDA intends to announce the companies and devices selected for the interaction phase on its public-facing webpage. This public recognition can serve as a powerful signal to investors, partners, and potential customers that your device has been identified by FDA as a promising solution to a significant healthcare challenge. For early-stage companies, this validation can be particularly valuable for fundraising and business development.

What Happens After the Interaction Phase

The Challenge does not have a defined end date for the interaction phase, and it does not guarantee a specific regulatory outcome. After the interaction phase concludes, participants will still need to pursue the appropriate marketing pathway (510(k), De Novo, or PMA) through the standard process. The benefit is that they will have done so with the benefit of extensive early FDA engagement, a refined development plan, and potentially a BTD or STeP designation that provides additional process efficiencies during review.

Regulatory Considerations and Tensions

While the READI-Home Innovation Challenge represents a genuinely innovation-friendly signal from FDA, it exists within a broader regulatory context that contains significant tensions — particularly for certain categories of home-use devices. Companies considering a submission should understand these dynamics.

The Evidentiary Bar for Home-Use Diagnostics

One of the most significant tensions in FDA's approach to home-use devices concerns diagnostic and specimen collection devices. While the Challenge signals enthusiasm for home-based innovation, FDA's evidentiary expectations for home-use diagnostics remain high and, in some cases, have been inconsistent with the "least burdensome" principle that FDA has publicly committed to.

Developers of home specimen collection and diagnostic devices have continued to face substantial evidentiary expectations, driven by FDA concerns about:

Variable home environments: Temperature, humidity, lighting, and other environmental factors can affect device performance in unpredictable ways.
Lay user performance: Devices designed for use by untrained patients and caregivers may produce different results than when used by healthcare professionals. FDA's expectations for human factors validation of lay-user performance are rigorous.
Stability and shelf-life: Specimen collection kits and diagnostic reagents must maintain stability outside controlled laboratory conditions, requiring extensive stability testing under diverse conditions.
Method comparison: FDA typically requires robust method comparison studies demonstrating that home-use results are equivalent to those obtained in clinical settings.

These expectations often translate into extensive usability studies, stability testing programs, and method comparison data requirements that can add years to a development timeline and millions of dollars to a development budget. The Challenge does not explicitly relax any of these requirements — it provides earlier engagement to help sponsors navigate them more efficiently.

Human Factors Engineering for Home Use

FDA's emphasis on human factors engineering for home-use devices is both appropriate and challenging. Home environments are fundamentally different from clinical environments:

Factor	Clinical Setting	Home Setting
User training	Healthcare professionals with formal training	Patients and caregivers with varying literacy, dexterity, and cognitive abilities
Environmental control	Temperature, lighting, cleanliness controlled	Variable and unpredictable
Device maintenance	Biomedical engineering staff	Patient or family member following written instructions
Error detection	Multiple healthcare workers as safety net	Single user who may not recognize an error
Connectivity	Reliable hospital networks	Variable home internet and cellular connectivity
Supervision	Continuous monitoring by clinical staff	No supervision; device must guide the user

For READI-Home Challenge participants, this means that human factors engineering should be a central component of the Data Development Plan. FDA will expect to see evidence that the device has been designed to accommodate the realities of home use — not simply adapted from a clinical device.

Cybersecurity Considerations

Many devices that could reduce hospital readmissions are connected devices — they transmit data to healthcare providers, integrate with electronic health records, or connect to companion mobile applications. This introduces cybersecurity requirements that must be addressed:

FDA Section 524B (added to the FD&C Act by the Consolidated Appropriations Act of 2023) requires that cyber devices include cybersecurity measures and that sponsors submit a Software Bill of Materials (SBOM) as part of any marketing application.
The Quality Management System Regulation (QMSR), which took effect on February 2, 2026, integrates cybersecurity into the quality system requirements for medical devices.
Connected home-use devices present a larger attack surface than their clinical counterparts because they operate on uncontrolled networks and may be maintained by users with limited technical sophistication.

Sponsors should ensure that their Data Development Plan addresses cybersecurity testing, vulnerability management, and secure design principles from the outset.

The "Least Burdensome" Tension

FDA has repeatedly emphasized its commitment to the "least burdensome" standard — the principle that the agency should request the minimum amount of information necessary to make a regulatory decision. In practice, however, the application of this principle to home-use devices has been inconsistent. Some sponsors have reported that FDA's requests for home-use diagnostic devices have exceeded what would be required for the same technology in a clinical setting, without a clear justification for the additional burden.

The READI-Home Challenge may help to address this tension by creating a dedicated space for dialogue about the appropriate level of evidence for home-use devices. But sponsors should be aware that participation in the Challenge does not guarantee that FDA will adopt a less burdensome approach to their specific device. The regulatory standards remain the same; what changes is the process for arriving at them.

Designing for Equity

FDA's growing emphasis on health equity, particularly as reflected in the updated Breakthrough Devices Program guidance, has implications for READI-Home Challenge submissions as well. Devices that are designed to be accessible across diverse populations — considering factors such as language, literacy, physical ability, cultural context, and socioeconomic status — may be viewed more favorably. Sponsors should consider addressing health equity in their submissions, particularly in the sections on anticipated impact and data development plan.

Device Categories Well-Suited for the Challenge

While the Challenge is open to any device meeting the Section 201(h)(1) definition, certain device categories are particularly well-aligned with the program's goals and may be more competitive during selection:

Remote patient monitoring devices: Continuous or intermittent monitoring of vital signs, medication adherence, wound status, or other clinical parameters after discharge. These devices address the core Challenge objective of preventing readmissions through early detection of deterioration.
AI-enabled diagnostics: Devices that use artificial intelligence or machine learning to analyze patient-generated data and flag potential complications before they escalate to the point of readmission. The combination of home-based data collection and algorithmic analysis represents a rapidly growing area of FDA interest.
Caregiver-operated devices: Technologies specifically designed to be used by family members or non-professional caregivers, rather than patients alone. Given the Challenge's emphasis on patient and caregiver as intended users, devices that empower caregivers with clinical-grade tools are strong candidates.
Medication management and adherence technologies: Devices that help patients follow complex post-discharge medication regimens, which are a leading driver of preventable readmissions.
Connected specimen collection and at-home diagnostics: Devices enabling patients to collect specimens or perform diagnostic tests at home, with results transmitted to healthcare providers for clinical decision-making. Note that this category faces particularly high evidentiary expectations from FDA (see the section on regulatory tensions above).

Reimbursement and Market Access Considerations

One dimension that is easy to overlook in the excitement of an FDA innovation challenge is the commercial reality that regulatory clearance or approval is necessary but not sufficient for market success. A device that reduces readmissions must also be reimbursable — and reimbursement strategy should be developed in parallel with the regulatory strategy, not as an afterthought.

Several considerations are worth noting:

Medicare coverage: Hospital readmissions are a major cost driver for the Centers for Medicare & Medicaid Services (CMS). The Hospital Readmissions Reduction Program (HRRP) already penalizes hospitals with excess readmissions for certain conditions, creating a financial incentive for hospitals to adopt technologies that reduce readmission rates. Devices that can demonstrate readmission reduction may find a receptive audience among both CMS and hospital systems.
The FDA-CMS RAPID pathway: In 2026, FDA and CMS jointly announced the RAPID (Regulatory Alignment for Predictable and Immediate Device) coverage pathway, which aims to align FDA regulatory review and Medicare coverage planning much earlier in the process for breakthrough devices. While READI-Home is separate from RAPID, selected participants who also receive Breakthrough Device designation could benefit from both programs, creating a synergistic pathway from regulatory approval to patient access.
Commercial insurance: Coverage strategies should address not only Medicare but also Medicaid and commercial payers, each of which has different coverage criteria, coding requirements, and reimbursement mechanisms.
Timing: Developing a coverage and reimbursement strategy contemporaneously with the FDA regulatory process — rather than sequentially — can significantly reduce the gap between regulatory approval and patient access.

For companies submitting to the READI-Home Challenge, the Data Development Plan section is an opportunity to signal awareness of these commercial considerations. Including evidence generation strategies that address both regulatory requirements and payer expectations can strengthen the submission and demonstrate commercial readiness.

How to Position Your Company

If you are considering a submission to the READI-Home Innovation Challenge, here is a practical framework for preparing your application.

Step 1: Assess Fit Against the Five Elements (Now)

Before investing in a submission, honestly evaluate your device against the five prioritization elements. Ask:

Does our device address an unmet or emerging healthcare need in the home setting? Can we articulate this clearly?
Is at least one intended user a patient or caregiver (not just a trained healthcare professional)?
Is at least one intended use environment the patient's home or community?
Do we have evidence — even preliminary evidence — that our device could reduce readmissions? Literature-based evidence is acceptable at this stage.
Have we demonstrated feasibility through a proof of concept, prototype, or preliminary testing?

If you cannot answer "yes" to all five questions, assess whether you can credibly address the gaps before the September 30, 2026 submission deadline.

Step 2: Develop Your Data Development Plan (April - June 2026)

The Data Development Plan (DDP) is one of the most important components of your submission. It signals to FDA that you have a credible, well-thought-out path from where you are today to a future marketing application. A strong DDP should include:

Bench testing plan: What performance testing is needed, and how will it address home-use conditions?
Human factors engineering plan: How will you evaluate and validate that the device can be used safely and effectively by lay users in a home environment?
Clinical evidence plan: If clinical data is needed, what study design is proposed? What endpoints? What population? How does it relate to the readmission reduction claim?
Regulatory pathway analysis: What marketing pathway (510(k), De Novo, PMA) do you intend to pursue, and what evidence is required for that pathway?
Timeline: A realistic development timeline from current status through marketing authorization.

Step 3: Attend the FDA Webinar (June 24, 2026)

The FDA webinar on June 24, 2026 is a critical information-gathering opportunity. Come prepared with specific questions about:

How FDA interprets each of the five prioritization elements
What level of feasibility evidence is expected at the submission stage
How BTD/STeP consideration will be integrated into the selection process
What the interaction phase will look like in practice — frequency of meetings, format, duration
How FDA is thinking about evidentiary expectations for home-use diagnostics specifically

The presentation slides and transcript will be available afterward, but live attendance allows you to ask questions and hear answers to other participants' questions in real time.

Step 4: Draft and Refine Your Submission (June - August 2026)

With 16 pages total (including the 1-page executive summary), every word must earn its place. Best practices for drafting:

Lead with the executive summary: Draft it last, after the supporting documentation is complete, so you can distill the strongest points.
Address each element explicitly: Do not make FDA guess how your device meets the five prioritization elements. Use clear headings and direct language.
Be honest about development status: Overstating your progress will be discovered during the interaction phase and will damage credibility.
Support claims with evidence: Every assertion about potential readmission reduction, clinical impact, or technical feasibility should be backed by data, literature, or a clear rationale.
Get regulatory review: Have an experienced regulatory professional review the submission before it is finalized. The Q-submission format and the submission purpose language must be exact.

Step 5: Submit Early (August - September 2026)

While the deadline is September 30, 2026, there are practical reasons to submit early:

Technical issues: The CDRH portal can experience delays or technical problems, especially near deadlines.
Clarification requests: FDA may request clarification or additional information before the submission period closes. Early submission gives you time to respond.
Demonstrated interest: While FDA has not stated that submission timing affects selection, early submission signals seriousness and preparation.

Step 6: Plan for Both Outcomes

Prepare for two scenarios:

If selected: Be ready to begin the interaction phase immediately on December 5, 2026. This means having your team aligned, your questions prioritized, and your development plan ready for sprint discussion. The interaction phase is an active collaboration, not a passive award — you need to be prepared to engage.

If not selected: The informational Q-submission remains on file with FDA. You can still submit subsequent Q-submissions related to your device, pursue BTD or STeP designation independently, and continue development through standard regulatory channels. Not being selected does not prejudice your future interactions with FDA. Moreover, the process of preparing a submission is itself valuable — it forces clarity about your device's value proposition, development plan, and regulatory strategy.

Key Takeaways

Topic	Key Point
What it is	An FDA CDRH Innovation Challenge to accelerate home-use medical devices that reduce hospital readmissions
Announced	April 7, 2026, as part of the Home as a Health Care Hub initiative
Who can apply	Any company with a device meeting the Section 201(h)(1) definition that addresses unmet needs in home-based care
How many selected	Up to 9 participants
Submission deadline	September 30, 2026
How to submit	Informational Q-submission via CDRH portal with "READI-Home Innovation Challenge" prefix
Selection by	December 4, 2026
Interaction phase starts	December 5, 2026
Key benefits	Sprint discussions, FDA facility demos, BTD/STeP consideration, public recognition
Critical caveat	Does not constitute premarket approval; evidentiary standards unchanged
Well-suited device types	Remote monitoring, AI-enabled diagnostics, caregiver-operated devices, medication adherence technologies, connected home diagnostics
Commercial consideration	Develop reimbursement strategy in parallel with regulatory strategy; BTD-selected participants may also benefit from FDA-CMS RAPID pathway
FDA webinar	June 24, 2026, 1:00 - 2:00 PM ET (Microsoft Webinar, registration required)
Contact	HealthHomeHub@fda.hhs.gov (subject: "READI-Home Innovation Challenge Inquiry")

The READI-Home Innovation Challenge represents a meaningful opportunity for device developers to shape the future of home-based healthcare while gaining structured access to FDA expertise. The companies that will benefit most are those that come prepared with a clear value proposition, credible evidence of feasibility, and a well-constructed plan for generating the data needed to bring their device to market. The submission window is open now — the question is whether your device is ready to answer the call.